Business
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimabSAN DIEGO, Jan. 5, 2026 /PRNewswire/
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimabSAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme's ENHANZE® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye's evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes.\"Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market, a therapeutic area with significant long-term potential,\" said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. \"This agreement reinforces the scalability of ENHANZE across diverse indications and supports our strategy to drive sustainable royalty growth with new partnerships and innovations.\"\"To fully evaluate nimacimab's potential, we need to test higher doses and we need a practical way to deliver them subcutaneously,\" said Punit Dhillon, President and Chief Executive Officer of Skye. \"Partnering with Halozyme to co-formulate nimacimab with ENHANZE gives us a validated approach to evaluate multiple dose-ranging strategies, including in combination with GLP-1 receptor agonists.\"Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE® for at least 10 years.Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.About HalozymeHalozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reduci...